The influence of 18flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma

American Journal of Surgery

Volumn 197, Issue 3, 2009, Pages 308-312

  Smith, Jason W ^a   Moreira, Jonathan ^a   Abood, Gerard ^a   Aranha, Gerard V ^a   Nagda, Suneel ^a   Wagner, Robert H ^a   Shoup, Margo ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Esophageal carcinoma; Esophagectomy; Esophagogastric junction; FDG JPET; Gastric carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG UPTAKE; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; IMAGING SYSTEM; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH CARCINOMA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADENOCARCINOMA; AGED; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 60549105210     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.10.010     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Albano J.D., Ward E., Jemal A., et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst 99 (2007) 1384-1394
3. Pisani P., Parkin D.M., Bray F., et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83 (1999) 18-29
4. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
5. Sauvanet A., Mariette C., Thomas P., et al. Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors. J Am Coll Surg 201 (2005) 253-262
6. Hofstetter W., Swisher S.G., Correa A.M., et al. Treatment outcomes of resected esophageal cancer. Ann Surg 236 (2002) 376-75
7. Enzinger P.C., and Mayer R.J. Esophageal cancer. N Engl J Med 349 (2003) 2241-2252
8. Schmidt G.P., Kramer H., Reiser M.F., et al. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology. Top Magn Reson Imaging 18 (2007) 193-202
9. Ott K., Weber W., and Siewert J.R. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 19 (2006) 433-442
10. Juweid M.E., and Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354 (2006) 496-507
11. Flamen P., Lerut A., Van Cutsem E., et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18 (2000) 3202-3210
12. Downey R.J., Akhurst T., Ilson D., et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21 (2003) 428-432
13. McDonough P.B., Jones D.R., Shen K.R., et al. Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer?. A prospective single center study. Am J Gastroenterol 103 (2008) 570-574
14. van Westreenen H.L., Westerterp M., Sloof G.W., et al. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 94 (2007) 1515-1520
15. Siewert J.R., and Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85 (1998) 1457-1459
16. In: Greene F.L., Fleming I., and Fritz A. (Eds). AJCC cancer staging manual. 6th ed. (2003), Lippincott-Raven
17. Meyers B.F., Downey R.J., Decker P.A., et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 133 (2007) 738-745
18. Ott K., Weber W.A., Lordick F., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24 (2006) 4692-4698
19. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON Phase II trial. Lancet Oncol 8 (2007) 797-805
20. Wieder H.A., Ott K., Lordick F., et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 34 (2007) 1925-1932